Comparative Pharmacology
Head-to-head clinical analysis: HICON versus OXYBUTYNIN CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus OXYBUTYNIN CHLORIDE.
HICON vs OXYBUTYNIN CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Oxybutynin chloride is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), leading to relaxation of the detrusor muscle and reduction of urinary bladder contractions.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (100 mg) applied once daily.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 12–13 hours in plasma; clinical effect may persist longer due to active metabolite (N-desethyloxybutynin, half-life ~12–13 hours).
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily hepatic metabolism; <0.1% excreted unchanged in urine. Metabolites (e.g., N-desethyloxybutynin) excreted mainly renally. Fecal elimination <0.02%.
Category C
Category A/B
Anticholinergic
Anticholinergic